SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 18
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 15 16 17 18
|
presentations:
1 to
50 of
868
|
WELCOME AND SESSION OVERVIEW: PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES (ABSTRACT
1a)
Nicolas Chomont
Université de Montréal, Montreal, Canada
Serena S Spudich
Yale University, New Haven, CT, USA
ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-COV-2
Frank Kirchhoff
Ulm University Medical Center, Ulm, Germany
ADVANCES IN HIV AND SARS-COV-2 IMMUNOLOGY
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC
Jürgen K Rockstroh
Medizinische Universitatsklini, Bonn, Germany
ADVANCES IN BIOMEDICAL PREVENTION OF HIV
Jean-Michel Molina
University of Paris, Paris, France
ADVANCES IN HIV CURE
Katharine J Bar
University of Pennsylvania, Philadelphia, PA, USA
GENERAL Q&A AND SESSION WRAP-UP
Nicolas Chomont
Université de Montréal, Montreal, Canada
Serena S Spudich
Yale University, New Haven, CT, USA
CHAIRS WELCOME TO VIRTUAL CROI 2021
Sharon L. Hillier
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
INTRODUCTION TO THE MARTIN DELANEY PRESENTATION
James Pickett
AIDS Foundation of Chicago, Chicago, IL, USA
VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-COV-2 VACCINES WILL PERPETUATE THE PANDEMIC (ABSTRACT
2a)
Gregg S. Gonsalves
Yale University, New Haven, CT, USA
Fatima Hassan
Health Justice Initiative, Cape Town, South Africa
INTRODUCTION TO THE BERNARD FIELDS LECTURE
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
NEUTRALIZING ANTIBODIES AGAINST CORONAVIRUSES (ABSTRACT
3)
Pamela J Bjorkman
California Institute of Technology, Pasadena, CA, USA
INTRODUCTION TO THE N'GALY-MANN LECTURE
Elaine J Abrams
Columbia University, New York, NY, USA
Tedros Adhanom Ghebreyesus
World Health Organization, Geneva, Switzerland
LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET (ABSTRACT
4)
Anthony S Fauci
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
SESSION OVERVIEW
Robert T Schooley
University of California San Diego, La Jolla, CA, USA
David L Thomas
The Johns Hopkins School of Medicine, Baltimore, MD, USA
RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19 (ABSTRACT
11)
Kwok-Yung Yuen
The University of Hong Kong, Hong Kong, Hong Kong
COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS (ABSTRACT
12)
Sanjay Bhagani
Royal Free Hospital, London, United Kingdom
CRITICAL CARE OF COVID-19 (ABSTRACT
13)
Janhavi Athale
Mayo Clinic Arizona, Phoenix, AZ, USA
QUESTIONS AND ANSWERS WITH THE AUDIENCE
SESSION OVERVIEW
Susan P Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
Richard E Chaisson
The Johns Hopkins University, Baltimore, MD, USA
MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS (ABSTRACT
9)
Lori Dodd
National Institutes of Health, Bethesda, MD, USA
DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS (ABSTRACT
10)
Holly Janes
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
LIVE QUESTIONS AND ANSWERS WITH THE AUDIENCE
SESSION OVERVIEW
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Frank Kirchhoff
Ulm University Medical Center, Ulm, Germany
STRUCTURES OF SARS-COV-2 ANTIBODIES INDUCED BY INFECTION AND MRNA VACCINES (ABSTRACT
5)
Christopher O Barnes
California Institute of Technology, Pasadena, CA, USA
EMERGING CONCEPTS IN HIV-1 RESTRICTION (ABSTRACT
6)
Edward Campbell
Loyola University Chicago, Maywood, IL, USA
SARS-COV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES (ABSTRACT
7)
Daniela Weiskopf
La Jolla Institute for Immunology, La Jolla, CA, USA
ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING (ABSTRACT
8)
Sai Reddy
ETH Zurich, Basel, Switzerland
DOES HIV IMPACT COVID-19 SUSCEPTIBILITY OR SEVERITY? (ABSTRACT
31)
Julia Del Amo
Ministry of Health, Madrid, Spain
THE IMPACT OF COVID-19 ON THE HIV PANDEMIC WORLDWIDE (ABSTRACT
32)
Andrew D Kambugu
Makerere University, Kampala, Uganda
THE IMPACT OF COVID-19 BEYOND HIV (ABSTRACT
33)
Helen Bygrave
International AIDS Society, London, United Kingdom
FEAR AND COVID-19: EXPERIENCES ON THE GROUND (ABSTRACT
34)
Francois Venter
Ezintsha, Johannesburg, South Africa
FROM GENOME TO FUNCTION: PHENOTYPIC CHARACTERISATION OF PANDEMIC SARS-COV-2 VARIANTS (ABSTRACT
23)
Volker Thiel
University of Bern, Bern, Switzerland
IMMUNE EVASION STRATEGIES BY SARS-COV-2: NSP1 AND BEYOND (ABSTRACT
24)
Konstantin Sparrer
Ulm University, Ulm, Germany
SHARED VULNERABILITIES AND DIFFERENT COUNTERMEASURES OF HIV AND SARS-COV-2 (ABSTRACT
25)
Eric O Freed
National Cancer Institute, Frederick, MD, USA
IMMUNE RESPONSES TO SARS-COV-2 (ABSTRACT
26)
Akiko Iwasaki
Yale University, New Haven, CT, USA
SYMPOSIUM CONVENER
Wesley I Sundquist
University of Utah School of Medicine, Salt Lake City, UT, USA
LIVE-CELL IMAGING: CAPSID TRAFFICKING TO THE NUCLEUS (ABSTRACT
19)
Barbara Müller
University Hospital Heidelberg, Heidelberg, Germany
LIVE-CELL IMAGING OF HIV-1 NUCLEAR IMPORT, UNCOATING, AND PROVIRUSES (ABSTRACT
20)
Vinay K Pathak
National Cancer Institute, Frederick, MD, USA
VISUALIZATION OF HIV-1 CAPSID-DEPENDENT REPLICATION IN VITRO (ABSTRACT
21)
Barbie Ganser-Pornillos
University of Virginia, Charlottesville, VA, USA
LENACAPAVIR (GS-6207): FIRST CLINICALLY ACTIVE LONG-ACTING INHIBITOR OF HIV CAPSID (ABSTRACT
22)
Tomas Cihlar
Gilead Sciences, Inc, Foster City, CA, USA
THE POTENTIAL OF LONG-ACTING INJECTABLE DRUGS FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (ABSTRACT
27)
Eric Nuermberger
Johns Hopkins University, Baltimore, MD, USA
PREGNANCY, HIV, AND TUBERCULOSIS: CURRENT PRACTICES AND RESEARCH OPPORTUNITIES (ABSTRACT
28)
Jyoti S Mathad
Weill Cornell Medical College, New York, NY, USA
ADVANCES IN PEDIATRIC TUBERCULOSIS PREVENTION AND TREATMENT (ABSTRACT
29)
Nicole Salazar-Austin
Johns Hopkins University School of Medicine, Baltimore, MD, USA
IMPACT OF COVID-19 PANDEMIC ON HIV AND TUBERCULOSIS: WHO PERSPECTIVE (ABSTRACT
30)
Souyma Swaminathan
World Health Organization, Geneva, Switzerland
WELCOME AND DAILY ROADMAP
Sharon L. Hillier
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
IMAGING VIRAL LIFE CYCLES (ABSTRACT
14)
Hans-Georg Kräusslich
Heidelberg University, Heidelberg, Germany
Wesley I Sundquist
University of Utah School of Medicine, Salt Lake City, UT, USA
DISPARITIES IN HEALTH: FROM HIV TO COVID-19 AND BEYOND (ABSTRACT
15)
James E.K. Hildreth
Meharry Medical College, Nashville, TN, USA
Carlos del Rio
Emory University, Atlanta, GA, USA
INTRODUCTION OF SPEAKERS (PART I)
Judith S Currier
University of California Los Angeles, Los Angeles, CA, USA
SHORT-COURSE ALENDRONATE FOR THE PREVENTION OF ART-ASSOCIATED BONE LOSS (ABSTRACT
96)
Tara McGinty
University College Dublin, Dublin, Ireland
|
<< first | < prev
page:
of 18
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 15 16 17 18
|
presentations:
1 to
50 of
868
|
